Kobayashi Pharmaceutical Co(JP:4967)
¥6,960.00-65.00 (-0.93%)
JP:4967
Kobayashi Pharmaceutical Co earnings date
¥6,960.00
At close:-65.00 (-0.93%)
Want to see JP:4967 full AI Analyst Report?
Kobayashi Pharmaceutical Co (4967) Q2 2024 Earnings Report
0 Followers
JP:4967 Q2 2024 EPS Results
- Actual EPS
- JPY 6.19
- Consensus EPS
- JPY 53.15
- Beat/Miss
- Missed by -JPY 46.96
- One Year Ago EPS
- JPY 55.92
JP:4967 Q2 2024 Revenue Results
- Actual Revenue
- JPY 36.65B
- Expected Revenue
- JPY 38.58B
- Beat/Miss
- Missed by -JPY 1.93B
- YoY Revenue Growth
- -8.73%
Earnings Announcement Details
- Quarter
- Q2 2024
- Date
- 08/08/2024
- Time
- TBA
- Conference Call
- Thursday, August 8, 2024
JP:4967 Upcoming Earnings
Kobayashi Pharmaceutical Co's next earnings date is estimated for February 16, 2027, based on past reporting schedules.
Q2 2024 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2024 Earnings Slide Deck
Q2 2024 Earnings Call Summary
No earnings call summary is available for this earnings event.
JP:4967 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 16, 2027 | 2026 (Q4) | 43.05- | -42.41 | ― | ― |
| Nov 10, 2026 | 2026 (Q3) | 64.5788.80 | 48.99 | 81.26% (+39.81) | |
| Aug 06, 2026 | 2026 (Q2) | 24.211.34 | 20.75 | -93.54% (-19.41) | |
| May 08, 2026 | 2026 (Q1) | 5.3813.95 | 21.86 | -36.18% (-7.91) | |
| Feb 10, 2026 | 2025 (Q4) | 81.80-42.41 | 63.52 | -166.77% (-105.93) | |
| Nov 11, 2025 | 2025 (Q3) | 43.9348.99 | 52.58 | -6.83% (-3.59) | |
| Aug 05, 2025 | 2025 (Q2) | 24.0320.75 | 6.19 | 235.22% (+14.56) | |
| May 09, 2025 | 2025 (Q1) | 50.0221.86 | 13.13 | 66.49% (+8.73) | |
| Feb 10, 2025 | 2024 (Q4) | 78.1363.52 | 56.55 | 12.33% (+6.97) | |
| Nov 08, 2024 | 2024 (Q3) | 82.3752.58 | 100.29 | -47.57% (-47.71) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed


